Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave...

Related Keywords

,Dave Mehalick ,Daniel Kontoh Boateng ,Colleen Delaney ,Karolinska Institutet ,David Schemelia ,Securities Exchange ,Exchange Commission ,Karolinska Institute ,Coeptis Therapeutics Holdings Inc ,Company Or Coeptis ,Deverra Therapeutics Inc ,Prnewswire Coeptis Therapeutics Holdings Inc ,Holdings Inc ,Drug Administration ,Coeptis Therapeutics Holdings ,Nasdaq ,University Of Pittsburgh ,Coeptis Therapeutics Inc ,Tiberend Strategic Advisors Inc ,Coeptis Pharmaceuticals Inc ,Therapeutics Holdings ,Deverra Therapeutics ,Chief Scientific ,Rapidly Advancing Clinical Programs ,Emerging Leader ,Natural Killer Cell ,Gene Meeting ,Coeptis Therapeutics ,Coeptis Pharmaceuticals ,Securities Act ,Securities Exchange Act ,Nasdaq Capital Market ,Strategic Advisors ,Markets ,